Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrahydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 0.57 |
| ▸ | GABRB2 known ✓ | P47870 | 5/20 | 0.57 |
| ▸ | GABRG2 known ✓ | P18507 | 3/20 | 0.57 |
| ▸ | GABRB3 known ✓ | P28472 | 3/20 | 0.57 |
| ▸ | GABRA2 known ✓ | P47869 | 3/20 | 0.57 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.57 |
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.53 |
| ▸ | KCNA1 known ✓ | Q09470 | 1/20 | 0.53 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.52 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.52 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.52 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.52 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.52 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.52 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.52 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.52 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.52 |
| ▸ | G6PD | P11413 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocortisone SCHEMBL11169159 | 1.00 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184192 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184193 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5610354 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1332665 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL4111245 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL193711 | 0.99 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5139991 | 0.98 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8366487 | 0.98 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL6461669 | 0.98 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114073703-A | Compositions and methods for treating nonalcoholic steatohepatitis | 苏州亚盛药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3638668-A1 | BICYCLIC HETEROAROMATIC UREA OR CARBAMATE COMPOUNDS FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3638667-A1 | BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| CN-110478510-A | A kind of rapidly tourniquet bandage | LOU LU | 2019-11-22 | — | — | CN | disclosed |
| CN-106967213-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-104428311-B | The hydrochloride salt of peptide and its purposes for immunotherapy is combined with other peptides | CIRCASSIA LTD. (GB) | 2019-11-01 | — | — | CN | disclosed |
| CN-109277109-B | Composite catalyst and preparation method thereof, application | 浙江新和成股份有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-109289886-B | PdIn alloy catalyst and preparation method thereof, application | 浙江新和成股份有限公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-106831894-B | A kind of method of deacetylation Coupling Adsorption separation D-Glucosamine Hydrochloride | 王惠 | 2019-08-30 | — | — | CN | disclosed |
| CN-110023297-A | SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | 詹森药业有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| CN-1037344-A | Therapeutically active cyclic methylene-1, 2-dicarboxylic acid amides, process for their preparation and pharmaceutical compositions containing them | GUIDOTTI & C SPA LABOR (IT) | 1989-11-22 | — | — | CN | disclosed |
| CN-1034724-A | WATER SOLUBLE CAMPTOTHECIN ANALOGS | SMITHKLINE BECKMAN CORP (US) | 1989-08-16 | — | — | CN | disclosed |
| CN-87104339-A | Separate in the L halfcystine hydrochloride-method of hydrate | — | 1988-06-01 | — | — | CN | disclosed |
| CN-86103997-A | The preparation method of triazolyl quinoline derivative class | — | 1987-12-30 | — | — | CN | disclosed |
| CN-86108737-A | The preparation method of sodium chloride aqueous solution and the production method of sodium bicarbonate | — | 1987-08-12 | — | — | CN | disclosed |
| CN-86108825-A | PYRIMIDINE DERIVATIVES | — | 1987-07-22 | — | — | CN | disclosed |
| CN-85103298-A | Process for preparing glyoxylylspermidine and its use for the preparation of 15-deoxyspergualin related compounds | — | 1987-01-21 | — | — | CN | disclosed |
| CN-85103264-A | 9a-azepine-9a-homoerythromycin derivative | — | 1987-01-14 | — | — | CN | disclosed |
| EP-0068171-A1 | Dihydropyridine compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1983-01-05 | — | — | EP | disclosed |